|
2. Etiologie
|
|
|
|
2.11 Etiologie - Alimentation
|
|
|
Processed meat? Really? How to process epidemiological news [The Mermaid's Tale]
|
|
|
|
|
|
Why
breast cancer, by the way? Why not intestinal or many other cancers?
Why, if even the current story refers to past results as being
'inconsistent' do we assume this one's right and they, or some of them,
were wrong? Could it be that this is because investigators want
attention, journalists need news stories, and so on?
|
|
|
|
|
|
|
2.5 Etiologie - Gènes
|
|
|
Time doesn’t heal all wounds: how DNA damage as we age causes cancer [The Conversation]
|
|
|
|
|
|
Our
research is helping to tease apart the contribution of DNA damage in
different disease processes. Our findings suggest that some people
accumulate more DNA damage than others – their clocks are ticking a
little faster – and measuring these differences may help to spot people
at risk of developing cancer, or help match them with more effective
treatments.
|
|
|
|
|
|
|
3.4.1 Chimioprévention - aspirine
|
|
|
|
Low-dose aspirin may lower ovarian cancer risk [Harvard]
|
|
|
|
|
|
For
this study, Harvard Chan School researchers, along with colleagues from
Brigham and Women’s Hospital in Boston and Moffitt Cancer Center in
Tampa, analyzed data on 205,498 women who were part of the Nurses’
Health Study and Nurses’ Health Study II. Of those, 1,054 developed
ovarian cancer.
|
|
|
|
|
|
|
|
Aspirin and Chemoprevention—Have We Arrived? [JAMA Oncology]
|
|
|
|
|
|
The
2 studies by Barnard et al and Simon et al are a critical step in
realizing a broader population-wide use of aspirin for cancer
chemoprevention. However, to realize the full potential of aspirin in
precision chemoprevention, the molecular underpinnings of these
important risk reduction effects also need to be defined.
|
|
|
|
|
|
|
4.12 Biopsies liquides
|
|
|
Guardant Health’s IPO Tops Range, Raising $238M for Cancer Tests [Xconomy]
|
|
|
|
|
|
To
date, Guardant has commercialized two liquid biopsy products.
Guardant360 launched in 2014, and tests for 73 cancer-related genes from
small amounts of tumor DNA circulating in the blood. Last year,
Guardant launched GuardantOMNI, which tests for 500 cancer genes. This
product is used in biopharmaceutical research, helping drug companies
identify cancer patients for clinical trials.
|
|
|
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
6.1 Observation
|
|
|
|
6.11 Patients
|
|
|
Male doctors said my ‘female’ cancer was incurable. Then a woman took command and gave me hope [STAT]
|
|
|
|
|
|
Like
most patients in the French system, my care was 100 percent covered by
the state, including the wig I eventually needed. And here, at last, a
woman took command of my care as the leader of an ovarian cancer
research project. This oncologist listened to my questions. She
explained medical approaches. She promised me that her goal was a cure
instead of surrender. And she was the very first to propose
immunotherapy, which harnesses the patient’s own immune system to attack
cancer.
|
|
|
|
|
|
|
6.14 Prix Nobel
|
|
|
Thoughts on the Chemistry Nobel Prize [In the Pipeline]
|
|
|
|
|
|
As
it stands, I see no real solution to the “That prize isn’t chemistry!”
problem. It’s a large enough field that molecular biology can be jammed
into it without (much) shame, and that brings us to another difficult
subject: there have been more world-impacting discoveries in that field
over the last decades than there have been in chemistry.
|
|
|
|
|
|
|
6.3 Associations/Fondations
|
|
|
Precision medicine needs a business mindset in order to flourish [STAT]
|
|
|
|
|
|
Bringing
five cancer organizations with different missions together to agree
upon a unified framework for reaching patients was no small feat. But
thanks to collective impact, they were able to agree on a common goal of
improving direct-to-patient engagement. And by working together,
instead of in silos, they created a promising framework they may not
have been able to develop on their own.
|
|
|
|
|
|
|
6.5 Médecines alternatives/complémentaires
|
|
|
|
6.6 Publications
|
|
|
|
|
6.7.1 IA/bioinformatique
|
|
|